Sangamo Biosciences (SGMO) 4.70 $SGMO Sangamo B
Post# of 273242
Posted On: 09/19/2016 9:12:38 PM
Sangamo Biosciences (SGMO) 4.70 $SGMO
Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX, The First Application Of Therapeutic In Vivo Genome Editing
PR Newswire - Tue Sep 06, 6:00AM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SB-FIX, the company's zinc finger nuclease (ZFN)-mediated genome editing product candidate for the treatment of hemophilia B. Sangamo expects to initiate a Phase 1/2 clinical study (SB-FIX-1501) in adult subjects with the disease in 2016.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces Participation At Upcoming Investor Conferences
PR Newswire - Wed Aug 31, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief executive officer, will provide an update on the Company's therapeutic development programs at the following conferences in September.
SGMO: 4.70 (+0.13)
The Alliance for Regenerative Medicine Welcomes New Vice Chairman Matthew Patterson, President and CEO, Audentes Therapeutics
Marketwired - Thu Aug 11, 8:00AM CDT
WASHINGTON, DC--(Marketwired - Aug 11, 2016) - The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, announced today that Matthew Patterson, president and CEO, Audentes Therapeutics, Inc., has been named vice chairman of ARM, effective immediately.
BOLD: 15.09 (+0.81), SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces Presentation At The 2016 Wedbush PacGrow Healthcare Conference
PR Newswire - Tue Aug 09, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief executive officer, will provide an overview of the company's business strategy and an update on Sangamo's therapeutic development programs at 8:35 am ET on Tuesday, August 16, 2016, at the 2016 Wedbush PacGrow Healthcare Conference. The conference is being held in New York.
SGMO: 4.70 (+0.13)
Downgrade Alert for Sangamo Biosciences (SGMO)
Comtex SmarTrend(R) - Fri Aug 05, 3:09AM CDT
Sangamo Biosciences (NASDAQ:SGMO) was downgraded from Buy to Neutral at Janney Montgomery today. The stock closed yesterday at $4.86 on volume of 5.0 million shares, above average daily volume of 770,000. There is potential upside of 318.4% for shares of Sangamo Biosciences based on a current price of $4.86 and an average consensus analyst price target of $20.33. The stock should run into initial resistance at its 50-day moving average (MA) of $6.15 and subsequent resistance at its 200-day MA of $7.06.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Reports Second Quarter 2016 Financial Results
PR Newswire - Wed Aug 03, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its second quarter 2016 financial results and updated on recent events and development timelines for its preclinical and clinical therapeutic programs.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces Second Quarter 2016 Conference Call and Webcast
PR Newswire - Wed Jul 27, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that the company will release its second quarter 2016 financial results after the market closes on Wednesday, August 3, 2016. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II
PR Newswire - Mon Jun 20, 6:00AM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application (IND) for SB-913, a zinc finger nuclease (ZFN)-mediated approach designed as a single treatment with the potential to provide a long-lasting therapy for Mucopolysaccharidosis Type II (MPS II, Hunter syndrome). The IND is now active and enables Sangamo to initiate a Phase 1/2 clinical trial (SB-913-1602) to assess the safety, tolerability and potential efficacy of SB-913 in adults with MPS II.
SGMO: 4.70 (+0.13)
Global Thalassemia Market Report: 2016 Edition - Gene Therapy for Curing Thalassemia/ Advances in Iron Chelation Therapy / Fetal Hemoglobin Inducers - Research and Markets
BusinessWire - Fri Jun 10, 4:19AM CDT
Research and Markets has announced the addition of the "Global Thalassemia Market Report: 2016 Edition" report to their offering.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces Presentation at the Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's founder and former president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 8:30 am ET on Wednesday, June 8, 2016, at the Jefferies 2016 Healthcare Conference. Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's newly appointed president and chief executive officer will also be attending the conference, which is being held in New York from June 7-10, 2016.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named As Successor
PR Newswire - Wed Jun 01, 6:00AM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today announced the company has appointed Alexander 'Sandy' Macrae, M.B., Ch.B, Ph.D., MRCP, as president and chief executive officer to succeed current president and CEO, Edward Lanphier. Mr. Lanphier is retiring from the day-to-day leadership of Sangamo. He will continue as a member of the board of directors and, as previously disclosed, will assume the chairmanship of the board immediately following the 2016 annual meeting of stockholders which will be held on June 14, 2016. Mr. William Ringo, Sangamo's current chairman since 2010, will remain on the board as chairman of the Nominating and Governance Committee and member of the Compensation Committee. Dr. Macrae has assumed the CEO role effective today.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Reports First Quarter 2016 Financial Results
PR Newswire - Mon May 02, 3:05PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its first quarter 2016 financial results and accomplishments.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces Presentation At The Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Thu Apr 28, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 9:20 am ET on Thursday, May 5, 2016, at the Deutsche Bank 41st Annual Health Care Conference. The conference is being held in Boston from May 4-5, 2016.
SGMO: 4.70 (+0.13), DB: 12.97 (-0.41)
Sangamo BioSciences Announces First Quarter 2016 Conference Call and Webcast
PR Newswire - Mon Apr 25, 3:03PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced that the company will release its first quarter 2016 financial results after the market closes on Monday, May 2, 2016. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces Presentations On ZFP Therapeutic® Programs And Applications At 2016 Annual Meeting Of The American Society Of Gene & Cell Therapy
PR Newswire - Mon Apr 18, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that data from several ZFP Therapeutic programs will be presented at the 19th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) to be held in Washington, D.C. from May 4-7, 2016.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Reports Fourth Quarter And Full Year 2015 Financial Results
PR Newswire - Tue Feb 09, 3:03PM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its fourth quarter and full year 2015 financial results and accomplishments.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX, The First Application Of Therapeutic In Vivo Genome Editing
PR Newswire - Tue Sep 06, 6:00AM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SB-FIX, the company's zinc finger nuclease (ZFN)-mediated genome editing product candidate for the treatment of hemophilia B. Sangamo expects to initiate a Phase 1/2 clinical study (SB-FIX-1501) in adult subjects with the disease in 2016.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces Participation At Upcoming Investor Conferences
PR Newswire - Wed Aug 31, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief executive officer, will provide an update on the Company's therapeutic development programs at the following conferences in September.
SGMO: 4.70 (+0.13)
The Alliance for Regenerative Medicine Welcomes New Vice Chairman Matthew Patterson, President and CEO, Audentes Therapeutics
Marketwired - Thu Aug 11, 8:00AM CDT
WASHINGTON, DC--(Marketwired - Aug 11, 2016) - The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, announced today that Matthew Patterson, president and CEO, Audentes Therapeutics, Inc., has been named vice chairman of ARM, effective immediately.
BOLD: 15.09 (+0.81), SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces Presentation At The 2016 Wedbush PacGrow Healthcare Conference
PR Newswire - Tue Aug 09, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief executive officer, will provide an overview of the company's business strategy and an update on Sangamo's therapeutic development programs at 8:35 am ET on Tuesday, August 16, 2016, at the 2016 Wedbush PacGrow Healthcare Conference. The conference is being held in New York.
SGMO: 4.70 (+0.13)
Downgrade Alert for Sangamo Biosciences (SGMO)
Comtex SmarTrend(R) - Fri Aug 05, 3:09AM CDT
Sangamo Biosciences (NASDAQ:SGMO) was downgraded from Buy to Neutral at Janney Montgomery today. The stock closed yesterday at $4.86 on volume of 5.0 million shares, above average daily volume of 770,000. There is potential upside of 318.4% for shares of Sangamo Biosciences based on a current price of $4.86 and an average consensus analyst price target of $20.33. The stock should run into initial resistance at its 50-day moving average (MA) of $6.15 and subsequent resistance at its 200-day MA of $7.06.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Reports Second Quarter 2016 Financial Results
PR Newswire - Wed Aug 03, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its second quarter 2016 financial results and updated on recent events and development timelines for its preclinical and clinical therapeutic programs.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces Second Quarter 2016 Conference Call and Webcast
PR Newswire - Wed Jul 27, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that the company will release its second quarter 2016 financial results after the market closes on Wednesday, August 3, 2016. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II
PR Newswire - Mon Jun 20, 6:00AM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application (IND) for SB-913, a zinc finger nuclease (ZFN)-mediated approach designed as a single treatment with the potential to provide a long-lasting therapy for Mucopolysaccharidosis Type II (MPS II, Hunter syndrome). The IND is now active and enables Sangamo to initiate a Phase 1/2 clinical trial (SB-913-1602) to assess the safety, tolerability and potential efficacy of SB-913 in adults with MPS II.
SGMO: 4.70 (+0.13)
Global Thalassemia Market Report: 2016 Edition - Gene Therapy for Curing Thalassemia/ Advances in Iron Chelation Therapy / Fetal Hemoglobin Inducers - Research and Markets
BusinessWire - Fri Jun 10, 4:19AM CDT
Research and Markets has announced the addition of the "Global Thalassemia Market Report: 2016 Edition" report to their offering.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces Presentation at the Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's founder and former president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 8:30 am ET on Wednesday, June 8, 2016, at the Jefferies 2016 Healthcare Conference. Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's newly appointed president and chief executive officer will also be attending the conference, which is being held in New York from June 7-10, 2016.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named As Successor
PR Newswire - Wed Jun 01, 6:00AM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today announced the company has appointed Alexander 'Sandy' Macrae, M.B., Ch.B, Ph.D., MRCP, as president and chief executive officer to succeed current president and CEO, Edward Lanphier. Mr. Lanphier is retiring from the day-to-day leadership of Sangamo. He will continue as a member of the board of directors and, as previously disclosed, will assume the chairmanship of the board immediately following the 2016 annual meeting of stockholders which will be held on June 14, 2016. Mr. William Ringo, Sangamo's current chairman since 2010, will remain on the board as chairman of the Nominating and Governance Committee and member of the Compensation Committee. Dr. Macrae has assumed the CEO role effective today.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Reports First Quarter 2016 Financial Results
PR Newswire - Mon May 02, 3:05PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its first quarter 2016 financial results and accomplishments.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces Presentation At The Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Thu Apr 28, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 9:20 am ET on Thursday, May 5, 2016, at the Deutsche Bank 41st Annual Health Care Conference. The conference is being held in Boston from May 4-5, 2016.
SGMO: 4.70 (+0.13), DB: 12.97 (-0.41)
Sangamo BioSciences Announces First Quarter 2016 Conference Call and Webcast
PR Newswire - Mon Apr 25, 3:03PM CDT
Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced that the company will release its first quarter 2016 financial results after the market closes on Monday, May 2, 2016. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Announces Presentations On ZFP Therapeutic® Programs And Applications At 2016 Annual Meeting Of The American Society Of Gene & Cell Therapy
PR Newswire - Mon Apr 18, 3:03PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that data from several ZFP Therapeutic programs will be presented at the 19th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) to be held in Washington, D.C. from May 4-7, 2016.
SGMO: 4.70 (+0.13)
Sangamo BioSciences Reports Fourth Quarter And Full Year 2015 Financial Results
PR Newswire - Tue Feb 09, 3:03PM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its fourth quarter and full year 2015 financial results and accomplishments.
SGMO: 4.70 (+0.13)
(0)
(0)Scroll down for more posts ▼